Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Pio Manlio Mirko Frascione,Mattia Novo,Alessia Castellino,Luigi Marcheselli, Samantha Deianira Dattoli,Alessandra Tucci,Guido Gini,Giuseppe Tarantini,Donato Mannina,Annalisa Arcari, Roberta Martiniani, Elisabetta Scarpa,Dario Marino,Michele Spina, Ausilia Giuseppa Gorgone,Nicola Di Renzo,Salvatrice Mancuso,Luigi Petrucci,Agostino Tafuri,Umberto Vitolo

Blood（2023）

引用 0|浏览8

暂无评分

摘要

Background: 60% of Diffuse large B-cell lymphoma (DLBCL) are cured with R-CHOP. Treatment options for relapsed/refractory (R/R) patients (pts) not eligible to high-dose chemotherapy and autologous stem cell transpntation (ASCT) or CAR-T are limited with short-lasting efficacy. The PI3-K inhibitor copanlisib showed activity in B-cell lymphomas including DLBCL. We reported the results of the phase II single arm multicenter FIL Copa-RB trial which investigated the combination copanlisib plus rituximab and bendamustine (copa-RB) in transplant-ineligible R/R DLBCL.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要